2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!
Apply Or Share this opportunity with the trainees in your network
— Deadline October 14, 2025.
The 2026 NMD4C/MDC Neuromuscular Fellowship Funding Competition is now open, offering early-career scientists the chance to receive salary support for postdoctoral studies in neuromuscular disease research. This annual competition, hosted by the Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC), aims to empower the next generation of researchers in building successful careers in neuromuscular disease research and clinical practice.
Key Details:
- Competition Opened: September 2nd, 2025
- Eligibility: Early-career scientists conducting postdoctoral studies in neuromuscular disease research.
- Funding: $40,000 over a one-year period.
- Application Deadline: October 14, 2025.
Eligibility and Selection Criteria
Eligibility and selection guidelines are available on our Neuromuscular Fellowship Funding Competition page with instructions on how to submit your application.
If you have any questions about the 2026 competition, please contact our Network Manager, Erin Beattie.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 26-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.